Business
Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy
CHICAGO, October 09, 2025--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to provide testing and contract research organization (CRO) services in support of the agency’s ADAPT (Advanced Analysis for Precision Cancer Therapy) program. The ADAPT program aims to revolutioni
About this update from Ai, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/673474ccf73c4be9c79496c3efb5a43f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6C7yfrfCCuy.nRnFtLtk0Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/673474ccf73c4be9c79496c3efb5a43f","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/7yQDx5ret5L_OCtv3FEU1Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/673474ccf73c4be9c79496c3efb5a43f","width":1024,"height":512}},"lazy":false},{"type":"text","content":"CHICAGO, October 09, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to provide testing and contract research organization (CRO) services in support of the agency’s ADAPT (Advanced Analysis for Precision Cancer Therapy) program. The ADAPT program aims to revolutionize cancer treatment by developing adaptive strategies that leverage biomarkers to target metastatic disease, initially focusing on non-small cell lung, breast, and colorectal cancers, with the ultimate goal of improving patient survival.","length":754,"tagName":"p"},{"type":"text","content":"As tumors evolve and develop resistance, clinicians face increasing challenges in determining the next course of therapy. The ADAPT program seeks to address this challenge by integrating computational models, novel biomarkers, and a new approach clinical trial design to enable early detection of tumor changes and informed treatment adjustments. Tempus will support the program by providing access to its portfolio of AI-enabled diagnostics, including xE, xR, xF+, xM, as well its CRO, Compass, to manage the trial’s operations across all participating sites. In addition, Tempus will leverage its data integration expertise to collect and harmonize the study’s data on behalf of the program.","length":693,"tagName":"p"},{"type":"text","content":""Tempus is proud to work with ARPA-H on the ADAPT program, whi...